The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 1, 2010, Pages 137-145

  Canis, K ^a   Mckinnon, T A J ^a   Nowak, A ^a   Panico, M ^a   Morris, H R ^b   Laffan, M ^a   Dell, A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b M SCAN Ltd   (United Kingdom)

Author keywords

Coagulation; O glycosylation; Von Willebrand factor

Indexed keywords

BLOOD GROUP ABH ANTIGEN; GLYCAN; VON WILLEBRAND FACTOR;

ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; GLYCOBIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN MOTIF; PROTEIN STRUCTURE;

ABO BLOOD-GROUP SYSTEM; AMINO ACID MOTIFS; CARBOHYDRATE CONFORMATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLYCOMICS; GLYCOSYLATION; HUMANS; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; TANDEM MASS SPECTROMETRY; VON WILLEBRAND FACTOR;

EID: 73049107203     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03665.x     Document Type: Article

References (30)

1. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature 1979, 279:636-8.
2. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977, 60:390-404.
3. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol 2003, 10:142-9.
4. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochemistry 1986, 25:3171-84.
5. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol 1986, 102:1320-4.
6. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 2008, 111:3042-9.
7. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem 1977, 252:5538-46.
8. Lawrence JB, Gralnick HR. Asialo-von Willebrand factor inhibits platelet adherence to human arterial subendothelium: discrepancy between ristocetin cofactor activity and primary hemostatic function. Blood 1987, 70:1084-9.
9. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992, 267:8723-31.
10. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987, 69:1691-5.
11. Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley AB, Evatt B. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003, 1:2191-7.
12. Davies JA, Collins PW, Hathaway LS, Bowen DJ. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. J Thromb Haemost 2008, 6:97-103.
13. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003, 1:33-40.
14. O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 2001, 11:343-51.
15. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, de Groot PG, Denis CV. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004, 279:12102-9.
16. Samor B, Michalski JC, Mazurier C, Goudemand M, De Waard P, Vliegenthart JF, Strecker G, Montreuil J. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J 1989, 6:263-70.
17. Carew JA, Quinn SM, Stoddart JH, Lynch DC. O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b. J Clin Invest 1992, 90:2258-67. doi
18. Schulte Am Esch J, Robson SC, Knoefel WT, Hosch SB, Rogiers X. O-linked glycosylation and functional incompatibility of porcine von Willebrand factor for human platelet GPIb receptors. Xenotransplantation 2005, 12:30-7. XEN187 [pii], doi
19. van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, Goudemand J, Fressinaud E, van den Berg HM, de Groot PG, Lenting PJ. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 2007, 109:2430-7.
20. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002, 22:335-41.
21. Jang-Lee J, North SJ, Sutton-Smith M, Goldberg D, Panico M, Morris H, Haslam S, Dell A. Glycomic profiling of cells and tissues by mass spectrometry: fingerprinting and sequencing methodologies. Methods Enzymol 2006, 415:59-86.
22. Ceroni A, Maass K, Geyer H, Geyer R, Dell A, Haslam SM. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res 2008, 7:1650-9.
23. Fukuda M, Lauffenburger M, Sasaki H, Rogers ME, Dell A. Structures of novel sialylated O-linked oligosaccharides isolated from human erythrocyte glycophorins. J Biol Chem 1987, 262:11952-7.
24. Yasukawa Z, Sato C, Sano K, Ogawa H, Kitajima K. Identification of disialic acid-containing glycoproteins in mouse serum: a novel modification of immunoglobulin light chains, vitronectin, and plasminogen. Glycobiology 2006, 16:651-65. cwj112 [pii], 10.1093/glycob/cwj112
25. Avril T, North SJ, Haslam SM, Willison HJ, Crocker PR. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression. J Leukoc Biol 2006, 80:787-96.
26. Teintenier-Lelievre M, Julien S, Juliant S, Guerardel Y, Duonor-Cerutti M, Delannoy P, Harduin-Lepers A. Molecular cloning and expression of a human hST8Sia VI (alpha2,8-sialyltransferase) responsible for the synthesis of the diSia motif on O-glycosylproteins. Biochem J 2005, 392:665-74. BJ20051120 [pii], doi
27. Storr SJ, Royle L, Chapman CJ, Hamid UM, Robertson JF, Murray A, Dwek RA, Rudd PM. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology 2008, 18:456-62.
28. Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, Vanhoorelbeke K, Deckmyn H. Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem 2006, 281:4699-707.
29. Yamaji T, Teranishi T, Alphey MS, Crocker PR, Hashimoto Y. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J Biol Chem 2002, 277:6324-32.
30. Hedlund M, Padler-Karavani V, Varki NM, Varki A. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci USA 2008, 105:18936-41.